Study Finds Remdesivir Does Little to Prevent COVID-19 Deaths
The Food and Drug Administration’s decision to grant a full approval to Gilead Sciences Inc.’s Veklury (remdesivir) is raising questions [...]
State Treasurers Call Out Gilead for Putting Remdesivir Profits Before Patients
State treasurers from Ohio, Pennsylvania, Nevada, Maine, Iowa, Oregon, Colorado, Wisconsin, Texas, Rhode Island, and Massachusetts asked Gilead Sciences (GILD) [...]
A Bridge Too Far: The High Cost of Gilead’s HIV Prevention Pill
A new analysis by U.S. government researchers found that the high cost of the world’s only HIV prevention pill may [...]
Invoke a 1980’s Law to Lower Cost of Remdesivir for COVID-19, says 31 State Attorneys General
A coalition of attorneys general (AG) have requested the U.S. Department of Health and Human Services to invoke a federal [...]
Report: Responses to Remdesivir Price Mostly Negative
Even though the Institute for Clinical for Economic Review (ICER) announced its support of remdesivir's pricing, the response has been [...]
Gilead CEO: Remdesivir Priced ‘Significantly’ Below Value to Society
Gilead CEO Daniel O'Day told STAT he's confident in the company's pricing decision for the COVID-19 drug remdesivir. "We spent [...]
Gilead Sets Price for Remdesivir
Gilead announced it would charge between $2,340 and $3,120 for a 5-day course of its COVID-19 drug remdesivir, BioPharma Dive [...]
ICER President: Remdesivir Price was ‘Responsible’ Decisions
The Institute for Clinical and Economic Review's president, Steven Pearson, says Gilead's decision to price its COVID-19 treatment remdesivir at [...]
Report: Gilead Poised to Sell $7.6 Billion of Remdesivir in 2022
Gilead could make as much as $7.6 billion in 2022 off its promising COVID-19 treatment remdesivir, according to Wall Street [...]
Post Spotlights ICER’s Remdesivir Pricing Models
The authors of a recent Health Affairs blog post highlight the Institution for Clinical and Economic Review's (ICER) pricing recommendations [...]
Article Covers Range of Opinions on Remdesivir Pricing
A recent STAT article offers the opinions of several experts on how much Gilead's COVID-19 treatment, remdesivir, should cost. While [...]
Winegarden: ICER’s Cost Model ‘Wrong,’ ‘Dangerous’
Wayne Winegarden, senior fellow in business and economics at the Pacific Research Institute, says the Institute for Clinical and Economic [...]
ICER Outlines Alternative Models for Judging Price of COVID-19 Treatments
The Institute for Clinical and Economic Review (ICER) recently recommended two alternative models for judging the "fairness" of pricing for [...]
ICER: Remdesivir Cost-effective at $4,460
The Institute for Clinical and Economic Review (ICER) has established a starting point for discussion about the price of Gilead's [...]
Inadvertent Release of Remdesivir Study Reveals Lackluster Results
An accidental release of study results of a clinical trial in China revealed Gilead's remdesivir failed to prevent patients from [...]
Report: Remdesivir Trials Posting Promising Results
Gilead's COVID-19 treatment, remdesivir, is showing some promise in clinical trials which have seen swift recoveries of symptoms in severe [...]
Report: Manufacturing Costs for Coronavirus Treatments Could Range on the Low End
Treatments for COVID-19, including hydroxychloroquine and remdesivir, could see very low manufacturing costs, according to a Bloomberg report. According to [...]
Coronavirus Patients Look to New Gilead Drug
As the world rushes to find a treatment for COVID-19, coronavirus patients are looking to secure a spot in studies [...]
